ABSTRACT

Introduction

Monoclonal antibodies binding the EGFR, such as cetuximab and panitumumab, have been extensively used as targeted therapy for the treatment of mCRC. However, in clinical practice, it has been found that these treatment options have some limitations and fail to fully exploit their immunoregulatory activities. Meanwhile, because of the limited effects of current treatments, immunotherapy is being widely studied for patients with mCRC. However, previous immunotherapy trials in mCRC patients have had unsatisfactory outcomes as monotherapy. Thus, combinatorial treatment strategies are being researched.

Areas covered

The authors retrieved relevant documents of combination therapy for mCRC from PubMed and Medline. This review elaborates on the knowledge of immunomodulatory effects of anti-EGFR therapy alone and in combination with immunotherapy for mCRC.

Expert opinion

Although current treatment options have improved median overall survival (OS) for advanced disease to 30 months, the prognosis remains challenging for those with metastatic disease. More recently, the combination of anti-EGFR therapy with immunotherapy has been shown activity with complementary mechanisms. Hence, anti-EGFR therapy in combination with immunotherapy may hold the key to improving the therapeutic effect of refractory mCRC.

中文翻译：

---

抗表皮生长因子受体 (EGFR) 疗法与免疫疗法相结合治疗转移性结直肠癌 (mCRC)

摘要

介绍

结合EGFR的单克隆抗体，例如西妥昔单抗和帕尼单抗，已广泛用作治疗转移性结直肠癌的靶向疗法。然而，在临床实践中，人们发现这些治疗方案存在一定的局限性，未能充分发挥其免疫调节活性。同时，由于目前治疗的效果有限，针对转移性结直肠癌患者的免疫疗法正在被广泛研究。然而，之前针对转移性结直肠癌患者的免疫治疗试验作为单一疗法的结果并不令人满意。因此，正在研究组合治疗策略。

覆盖领域

作者从 PubMed 和 Medline 检索了 mCRC 联合治疗的相关文献。本综述详细阐述了抗 EGFR 治疗单独治疗以及与免疫治疗联合治疗 mCRC 的免疫调节作用的知识。

专家意见

尽管目前的治疗方案已将晚期疾病的中位总生存期 (OS) 提高至 30 个月，但对于转移性疾病患者来说，预后仍然具有挑战性。最近，抗 EGFR 疗法与免疫疗法的组合已显示出具有互补机制的活性。因此，抗EGFR治疗联合免疫治疗可能是提高难治性转移性结直肠癌治疗效果的关键。